2018
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity
Leblanc A, Sprowl J, Alberti P, Chiorazzi A, Arnold W, Gibson A, Hong K, Pioso M, Chen M, Huang K, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen R, Reinbolt R, Lustberg M, Sucheston-Campbell L, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal Of Clinical Investigation 2018, 128: 816-825. PMID: 29337310, PMCID: PMC5785270, DOI: 10.1172/jci96160.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkersCell Line, TumorGenotypeHEK293 CellsHumansHyperalgesiaInhibitory Concentration 50Liver-Specific Organic Anion Transporter 1MCF-7 CellsMiceMice, Inbred DBAMice, KnockoutMice, TransgenicOrganic Anion TransportersPaclitaxelPeripheral Nervous System DiseasesPhenotypePyrimidinesConceptsPaclitaxel-induced neurotoxicityDose-limiting peripheral neurotoxicityTyrosine kinase inhibitor nilotinibAction potential amplitudeKinase inhibitor nilotinibPeripheral neurotoxicityThermal hyperalgesiaTherapeutic managementPotential amplitudeNeurotoxicityAnticancer propertiesNoncompetitive mechanismAnticancer drugsPaclitaxelAllodyniaHyperalgesiaPotential implicationsNilotinibOatp1b2Mice
2010
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerDynamic contrast magnetic resonance imagingWeekly nanoparticle albumin-bound paclitaxelNanoparticle albumin-bound paclitaxelClinical stage IIPhase II trialAlbumin-bound paclitaxelContrast magnetic resonance imagingMagnetic resonance imagingII trialResonance imagingStage IIBevacizumabCarboplatinChemotherapyCancerPaclitaxelTrials
2009
Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study
Lustberg M, Nuovo J, Thomas J, Monk P, Kim S, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. Journal Of Clinical Oncology 2009, 27: 2569-2569. DOI: 10.1200/jco.2009.27.15_suppl.2569.Peer-Reviewed Original ResearchDay 1Common grade 3/4 toxicitiesCapecitabine-based treatmentGrade 3/4 toxicitiesAdvanced solid tumorsExpression of TPThymidine phosphorylase activityAUC 6Carboplatin doseWeekly paclitaxelNeutropenic feverPrior therapyTherapeutic indexCapecitabineDose levelsSolid tumorsDay 8Dihydropyrimidine dehydrogenaseCarboplatinMalignant tissuesPhase IPaclitaxelNeutropeniaPatientsPhosphorylase activity